Back to Newsroom
Back to Newsroom

SHAREHOLDER ALERT: NEPT KDMN PCT: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

Wednesday, 12 May 2021 11:00 AM

The Law Offices of Vincent Wong

Topic:
Lawsuits

NEW YORK, NY / ACCESSWIRE / May 12, 2021 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.

Neptune Wellness Solutions Inc. (NASDAQ:NEPT)

If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/neptune-wellness-solutions-inc-loss-submission-form?prid=15752&wire=1
Lead Plaintiff Deadline: May 17, 2021
Class Period: July 24, 2019 - February 16, 2021

Allegations against NEPT include that: (i) the cost of Neptune's integration of the assets and operations acquired in the SugarLeaf Acquisition would be larger than the Company had acknowledged, placing significant strain on the Company's capital reserves; (ii) accordingly, it was reasonably foreseeable that the company would need to conduct additional stock offerings to raise more capital; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.

Kadmon Holdings, Inc. (NASDAQ:KDMN)

If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/kadmon-holdings-inc-loss-submission-form?prid=15752&wire=1
Lead Plaintiff Deadline: June 2, 2021
Class Period: October 1, 2020 - March 10, 2021

Allegations against KDMN include that: (i) the Belumosudil NDA was incomplete and/or deficient; (ii) the additional new data that the Company submitted in support of the Belumosudil NDA in response to an information request from the FDA materially altered the NDA submission; (iii) accordingly, the initial Belumosudil NDA submission lacked the degree of support that the Company had led investors to believe; (iv) accordingly, the FDA was likely to extend the PDUFA target action date to review the Belumosudil NDA; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.

PureCycle Technologies, Inc. (NASDAQ:PCT)

If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/purecycle-technologies-inc-loss-submission-form?prid=15752&wire=1
Lead Plaintiff Deadline: July 12, 2021
Class Period: November 16, 2020 - May 5, 2021

Allegations against PCT include that: (i) the technology PureCycle licensed from Procter & Gamble is not proven and presents serious issues even at lab scale; (ii) the challenges posed by the availability and competition for the raw materials necessary to commercialize the licensed technology are significant; (iii) PureCycle's financial projections are baseless; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

The Law Offices of Vincent Wong, Wednesday, May 12, 2021, Press release picture

To learn more contact Vincent Wong, Esq. either via email [email protected] or by telephone at 212.425.1140.

Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: [email protected]

SOURCE: The Law Offices of Vincent Wong

Topic:
Lawsuits
Back to newsroom
Back to Newsroom
Share by: